How can I get support with Lonsurf treatment?
You don’t have to do it alone when it comes to treatment with LONSURF. Once you enroll in the Taiho Oncology Patient Support program, you have the option to team up with a Nurse Navigator. He or she will help you by providing support over the phone concerning your treatment plan, including:
Where do I fill out the Lonsurf patient enrollment form?
1. You may have received this brochure in the LONSURF Starter Kit. If you Fill out a Patient Enrollment Form at your doctor’s offi ce with your doctor, nurse, or support staff. The offi ce can then fax the form to.
What is included in a Lonsurf patient brochure?
• Patient Brochure:Can help you understand what to expect from treatment, how to take LONSURF, tips that may help you manage side effects, and where to go for additional support.
What is the life expectancy of someone with Lonsurf?
In a clinical trial, half of the patients treated with LONSURF were still alive at 7.1 months and half of the patients who received placebo were still alive at 5.3 months. Worsening of the disease or death occurred in 88% of patients treated with LONSURF and 94% of patients who received placebo.
How effective is LONSURF?
On average, the time to cancer progression was 2 months for patients on Lonsurf compared to 1.7 months for patients receiving a placebo. Worsening of the disease or death occurred in 88% of patients treated with Lonsurf and 94% of patients who received placebo.
What company makes LONSURF?
LONSURF (trifluridine/tipiracil), discovered and developed by Taiho Pharmaceutical Co., Ltd., is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines.
What are the side effects of LONSURF?
The most common side effects with LONSURF include tiredness (fatigue, weakness), nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and fever. Tell your doctor if you have nausea, vomiting, or diarrhea that is severe or that does not go away. These are not all of the possible side effects of LONSURF.
When should I take LONSURF?
You will take LONSURF after morning and evening meals for 5 days a week, and then rest for 2 days. This goes on for 2 weeks. Then you will not take LONSURF for 2 weeks (14 days). This is repeated for as long as your healthcare provider says.
How long do people live on LONSURF?
In a clinical trial, half of the patients with metastatic stomach cancer treated with LONSURF were still alive at 5.7 months and half of the patients who received placebo were still alive at 3.6 months.
What is the world's largest chemotherapy company?
F. Hoffmann-La Roche LtdTop 20 pharma companies by oncology sales#CompanyGrowth ($m)1F. Hoffmann-La Roche Ltd16132Celgene Corp15153Novartis AG-10574Bristol-Myers Squibb Co26091 more row
Does LONSURF cause hair loss?
skin problems such as a rash, itchy or flaky skin or flushing – talk to your team about any changes to your skin. tummy pain. low levels of albumin in your body that can cause swelling and weakness. hair loss – this is usually temporary and grows back after treatment finishes.
Is LONSURF better than STIVARGA?
These agents were tested in very similar settings, but they have never been compared head-to-head. Stivarga was compared with placebo in a large study and it showed superiority to placebo in all parameters. Lonsurf was also compared with placebo and also showed an improvement in all efficacy parameters.
What class of drug is LONSURF?
Drug Type: Trifluridine/tipiricil is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor (for more detail, see "How Trifluidine/tipiricil Works" below).
Is 4 cycles of chemo enough?
Four cycles of adjuvant chemotherapy are sufficient for most breast cancer patients, according to results of a Phase III trial of 3,173 women reported at the CTCR-AACR San Antonio Breast Cancer Symposium.
How many cycles of chemotherapy do you need?
During a course of treatment, you usually have around 4 to 8 cycles of treatment. A cycle is the time between one round of treatment until the start of the next. After each round of treatment you have a break, to allow your body to recover.
Does Chemo get better or worse with each cycle?
Most types of pain related to chemotherapy get better or go away between individual treatments. However, nerve damage often gets worse with each dose. Sometimes the drug causing the nerve damage has to be stopped. It can take months or years for nerve damage from chemotherapy to improve or go away.
What company makes Tarceva?
Genentech: Tarceva® (erlotinib) - Information for Patients.
Who manufactures regorafenib?
Stivarga (Regorafenib) is an oral multikinase inhibitor developed by Bayer HealthCare for the treatment of metastatic colorectal cancer (mCRC). The US Food and Drug Administration (FDA) approved Stivarga in September 2012 for the treatment of mCRC patients.
Who owns Cyramza?
INDIANAPOLIS , May 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung ...
Who owns halaven?
This marks the Eisai Group's first product to be marketed by Eisai in Latin America. Halaven is an anticancer agent discovered and developed by Eisai. It is currently approved in more than 50 countries worldwide including Japan, the United States, and in Europe.
Is lonsurf safe for children?
LONSURF®(trifl uridine and tipiracil) is a prescription medicine used to treat people with colon or rectal cancer that has spread to other parts of the body and who have been previously treated with or cannot receive certain chemotherapy medicines. It is not known if LONSURF is safe and effective in children. In a clinical trial, half of the patients treated with LONSURF were still alive at 7.1 months and half of the patients who received placebo were still alive at 5.3 months. Worsening of the disease or death occurred in 88% of patients treated with LONSURF and 94% of patients who received placebo.
Does lonsufrf cause nausea?
with LONSURF include tiredness, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and fever. Tell your doctor if you have nausea, vomiting, or diarrhea that is severe or that does not go away. These are not all of the possible side effects of LONSURF. For more information, ask your healthcare provider. Call your doctor for medical advice about side effects.
What is a lonsuf?
LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu‑targeted therapy.
Can you breastfeed with lonsufrf?
There are no data to assess the effects of LONSURF or its metabolites on the breast‑fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.
What is a lonsuf?
LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu‑targetedtherapy.
What is the molar ratio of Lonsurf?
LONSURF®(trifluridine and tipiracil) tablets consist of a thymidine‑based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio, 1:0.471). Inclusion of tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase.
Can lonsurf harm the fetus?
Embryo‑Fetal Toxicity:LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the final dose.
Can you breastfeed with lonsufrf?
Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.
What is a lonsurf?
Lonsurf (tipiracil/trifluridine) is a member of the antineoplastic combinations drug class and is commonly used for Colorectal Cancer, and Gastric Cancer.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Is Lonsurf a generic?
Lonsurf is available as a brand name drug only, a generic version is not yet available. For more information, read about generic Lonsurf availability . This Lonsurf price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Can Prescription Hope Get My Lonsurf If I Have Health Insurance Coverage?
Because Prescription Hope is not a health insurance plan, our program works alongside any coverage you may currently have to obtain your Lonsurf medication at an affordable price. Our national advocacy program does not have medication tiers, copays, or deductibles.
Is Prescription Hope A Lonsurf Coupon Card, Generic, Or Insurance Product?
Prescription Hope is not a Lonsurf coupon card or insurance policy. Our program is also not a Lonsurf Generic. Prescription Hope is a national advocacy program that works with any coverage you may already have. Although Prescription Hope is not a Lonsurf coupon, individuals looking for a Lonsurf coupon can find more savings through Prescription Hope!
Warnings and Precautions
Use in Specific Populations
- Lactation:It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breast‑fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day followin…
Adverse Reactions
- Most Common Adverse Drug Reactions in Patients Treated With LONSURF (≥5%):The most common adverse drug reactions in LONSURF‑treated patients vs placebo‑treated patients with mCRC, respectively, were asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), infections (27% vs 16%), a…
Warnings and Precautions
- Severe Myelosuppression: LONSURF caused severe and life‑threatening myelosuppression (Grade 3‑4) consisting of neutropenia (38%), anemia (18%), thrombocytopenia (5%), and febrile neutropenia (3%). Two patients (0.2%) died due to neutropenic infection. A total of 12% of LONSURF‑treated patients received granulocyte‑colony stimulating factors. Obtain...
Use in Specific Populations
- Lactation:It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breast‑fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day followin…
Adverse Reactions
- Most Common Adverse Drug Reactions in Patients Treated With LONSURF (≥5%):The most common adverse drug reactions in LONSURF‑treated patients vs placebo‑treated patients with mCRC, respectively, were asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), infections (27% vs 16%), a…